Do Statins Counteract the Effect of Antidiabetic Drugs? Results of the SCEAD Study
Rattachement africain : tr, es, it. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Purpose: Diabetes and dyslipidemia are leading causes of mortality and morbidity.According to international guidelines, statins are the cornerstone of treatment in patients with diabetes and/or dyslipidemia.However, statins and antidiabetic agents have opposite pharmacological effects, because statins, particularly atorvastatin and rosuvastatin, impair glucose homeostasis, increasing the risk of new-onset diabetes, whereas antidiabetic drugs improve glycemic homeostasis.The aim of this study was to investigate the effect of atorvastatin, rosuvastatin, and pitavastatin on glucose homeostasis in patients with type 2 diabetes mellitus (T2DM) and dyslipidemia during stable treatment with hypoglycemic drugs. Materials and Methods:The study was conducted as a pilot, prospective, randomized, open label, parallel group with blindedendpoints (PROBE) study.Of 180 recruited patients with T2DM and dyslipidemia, 131 were randomized to atorvastatin (n=44), rosuvastatin (n=45), and pitavastatin (n=42) and treated for 6 months.Results: Fasting plasma glucose (FPG) marginally decreased in patients assigned to atorvastatin (-3.5 mg/dL, p=0.42) and rosuvastatin (-6.5 mg/dL, p=0.17), while it decreased much more in patients treated with pitavastatin (-19.0 mg /dL, p<0.001).Mean glycated hemoglobin A1c (HbA1c ) values remained unchanged during treatment with atorvastatin (-0.10%, p=0.53) and rosuvastatin (0.20%, p=0.40), but were significantly reduced with pitavastatin (-0.75%, p=0.01).Atorvastatin, rosuvastatin, and pitavastatin significantly lowered (p<0.001)plasma levels of total cholesterol, low-density lipoprotein-cholesterol, and triglycerides, while highdensity lipoprotein-cholesterol (HDL-C) levels increased significantly (p=0.04)only in the pitavastatin group. Conclusion:The results of the present study suggest that pitavastatin affects FPG and HbA1c less than atorvastatin and rosuvastatin in patients with T2DM and concomitant dyslipidemia.Lipid-lowering efficacies were not significantly different among the three statins, with the exception of HDL-C, which increased significantly with pitavastatin.Although the pharmacological mechanism of pitavastatin on glucose homeostasis in patients with T2DM during stable antidiabetic therapy is not known, it can be assumed that pitavastatin has less drug interaction with hypoglycemic agents or that it increases plasma levels of adiponectin.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Do Statins Counteract the Effect of Antidiabetic Drugs? Results of the SCEAD Study
- Date Crossref
- 01/01/2023
- Éditeur
- XMLink
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Dr Lütfi Kırdar Kartal Eğitim ve Araştırma Hastanesi pays non établi dans la noticeÉtablissement de santé
-
Universidad de Salamanca pays non établi dans la noticeUniversité ou école supérieure
-
University of Milano-Bicocca Medical Clinics pays non établi dans la noticeUniversité ou école supérieure
-
Izmir University Department of Cardiology pays non établi dans la noticeUniversité ou école supérieure
-
Denizli Devlet Hastanesi pays non établi dans la noticeÉtablissement de santé
-
Bayburt State Hospital pays non établi dans la noticeÉtablissement de santé
-
Istanbul University-Cerrahpaşa Department of Medical Pharmacology pays non établi dans la noticeUniversité ou école supérieure
-
Bahçeşehir University Department of Nephrology pays non établi dans la noticeUniversité ou école supérieure
-
Centro de Implantología Cirugía Oral y Maxilofacial pays non établi dans la noticeÉtablissement de santé
-
Kartal Research and Education Hospital Department of Internal Medicine pays non établi dans la noticeÉtablissement de santé
-
Salamanca University Department of Cardiovascular Risk pays non établi dans la noticeUniversité ou école supérieure
-
Milano-Bicocca University Department of Pharmacology pays non établi dans la noticeUniversité ou école supérieure
Dr Lütfi Kırdar Kartal Eğitim ve Araştırma Hastanesi, Universidad de Salamanca et Medical Clinics — University of Milano-Bicocca, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.